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Open access under CC BY-NC-ND license.BACKGROUND & AIMS: Etrolizumab is a humanized mono-
clonal antibody against the b7 integrin subunit that has shown
efficacy vs placebo in patients with moderate to severely active
ulcerative colitis (UC). Patients with colon tissues that
expressed high levels of the integrin aE gene (ITGAE) appeared
to have the best response. We compared differences in colonic
expression of ITGAE and other genes between patients who
achieved clinical remission with etrolizumab vs those who did.
METHODS: We performed a retrospective analysis of data
collected from 110 patients with UC who participated in a
phase 2 placebo-controlled trial of etrolizumab, as well as from
21 patients with UC or without inflammatory bowel disease
(controls) enrolled in an observational study at a separate site.
Colon biopsies were collected from patients in both studies and
analyzed by immunohistochemistry and gene expression
profiling. Mononuclear cells were isolated and analyzed by flow
cytometry. We identified biomarkers associated with response
to etrolizumab. In the placebo-controlled trial, clinical remis-
sion was defined as total Mayo Clinic Score 2, with no indi-
vidual subscore >1, and mucosal healing was defined as
endoscopic score 1. RESULTS: Colon tissues collected at
baseline from patients who had a clinical response to etroli-
zumab expressed higher levels of T-cellassociated genes than
patients who did not respond (P < .05). Colonic CD4þ integrin
aEþ cells from patients with UC expressed higher levels of
granzyme A messenger RNA (GZMA mRNA) than CD4þ aE
cells (P < .0001); granzyme A and integrin aE protein were
detected in the same cells. Of patients receiving 100 mg etro-
lizumab, a higher proportion of those with high levels of GZMA
mRNA (41%) or ITGAEmRNA (38%) than those with low levels
of GZMA (6%) or ITGAE mRNA (13%) achieved clinical remis-
sion (P < .05) and mucosal healing (41% GZMAhigh vs 19%
GZMAlow and 44% ITGAEhigh vs 19% ITGAElow). Compared with
ITGAElow and GZMAlow patients, patients with ITGAEhigh and
GZMAhigh had higher baseline numbers of epithelial crypt-
associated integrin aEþ cells (P < .01 for both), but a smaller
number of crypt-associated integrin aEþ cells after etrolizumabtreatment (P < .05 for both). After 10 weeks of etrolizumab
treatment, expression of genes associated with T-cell activation
and genes encoding inflammatory cytokines decreased by
40%80% from baseline (P < .05) in patients with colon
tissues expressing high levels of GZMA at baseline.
CONCLUSIONS: Levels of GZMA and ITGAE mRNAs in colon tis-
sues can identify patients with UC who are most likely to benefit
from etrolizumab; expression levels decrease with etrolizumab
administration in biomarkerhigh patients. Larger, prospective
studies of markers are needed to assess their clinical value.Keywords: IBD Drug; Response to Therapy; Anti-Integrin;
Personalized Medicine.
lcerative colitis (UC) is a chronic inflammatory dis-Uease of the colon. Current therapies, such as corti-
costeroids, immunosuppressants, and anti–tumor necrosis
factor (TNF) antibodies, are not universally effective at
induction and maintenance of remission,1 with z25% of
patients requiring colectomy.2 This variable response to
treatment and disease progression may reflect significant
heterogeneity in disease pathobiology.3,4 Improved stratifi-
cation driven by patient heterogeneity may help guide choice
of therapeutic intervention and enhance efficacy and safety.
The integrin-dependent migration and retention of leu-
kocytes to the gut plays an important role in the pathogenesis
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cells, including B cells, naïve and gut homing T cells, natural
killer (NK) cells, dendritic cells, stimulated macrophages,
monocytes, and eosinophils7 express a4b7 to mediate bind-
ing to mucosal addressin cell adhesion molecule 1 (MAd-
CAM-1) on high endothelial venules of Peyer’s patches,
mesenteric lymph nodes, and postcapillary venules of gut
lamina propria (LP).8 Interaction of a4b7 with MAdCAM-1
mediates the extravasation of naïve and activated leuko-
cytes from blood to gut-associated lymphoid tissues and the
LP. Increased MAdCAM-1 expression has been reported in
active UC.8,9 Recent studies that show induction of clinical
remission in UC patients after immunoblockade of leukocyte
trafficking support the importance of leukocyte homing in
disease pathobiology.1012
b7 integrin can also heterodimerize with aE integrin to
mediate binding to E-cadherin expressed on epithelial cells.
The aEb7 integrin is expressed on subsets of T cells, den-
dritic cells, mast cells,7 innate lymphoid cells,13 and tumor-
infiltrating NK cells.14 Within the gut, the interaction
between aEb7 and E-cadherin enables retention of lym-
phocytes in the intraepithelial compartment. More than
90% of intraepithelial lymphocytes (IELs) and a minority of
LP lymphocytes express aEb7.15 The proportion of mucosal
T cells that express aE was higher in intestinal tissues
compared with other organs, such as the lungs and spleen.16
aE expression has been shown to enhance IEL activation,17
promote antitumor cytotoxicity of T lymphocytes,18,19 and
modulate cell motility.20
The understanding of the role of aEb7 integrin in both
IEL and LP cells in the gut is evolving. In murine studies,
IELs can act as effector memory T cells to protect the
epithelium from pathogens.21 There is emerging evidence
that aEb7þ cells may play a pathogenic role in the gut, and
aberrant activation of aEb7þ cells may contribute to
inflammation and pathobiology of UC (unpublished data,
2014). aEb7þ memory CD8þ T cells with the capacity to
produce proinflammatory cytokines are highly enriched in
the gut compared with other tissues.16,22 aE þCD4þ and
CD8þ T cells from UC patients, but not control subjects, have
an effector phenotype with increased expression of proin-
flammatory cytokines compared with controls (unpublished
data, 2014). aEþ cells from the gut also have high levels of
perforin and granzyme A.23 aEþ intraepithelial type 1 innate
lymphoid cells were also found to be increased in patients
with Crohn’s disease and contribute to the inflammatory
process in anti-CD40induced murine colitis.13 Consistent
with this, anti-aE treatment has been shown to attenuate
experimental colitis in mice.24
Etrolizumab, a humanized monoclonal antibody against
the b7 integrin subunit, blocks both a4b7:MAdCAM-1 and
aEb7:E-cadherin interactions to reduce homing of leuko-
cytes to the gut mucosa and retention of lymphocytes in the
intraepithelial compartment, respectively. A recent phase
2 study of etrolizumab demonstrated efficacy relative to
placebo in patients with moderate to severely active UC.
Subsequent analyses of these data indicated that patients
with high aE gene expression or aEþ cell numbers in base-
line colonic biopsies might have increased benefit.11 In thecurrent study, we evaluated baseline differences in colonic
gene expression between patients who achieved clinical
remission with etrolizumab in the phase 2 study compared
with those who did not to identify additional predictive
biomarkers of response. The relationship of these genes with
etrolizumab therapeutic efficacy was then evaluated.Materials and Methods
Patient Cohorts
Two independent cohorts of patients were included in this
analysis: (1) UC patients enrolled in the phase 2 randomized
double-blind placebo-controlled trial of etrolizumab11 (referred
to as cohort 1) and (2) UC patients and non-IBD controls
concurrently enrolled in an observational study at a separate
site not involved in the phase 2 study (referred to as cohort 2)
(unpublished data, 2014). Predictive biomarkers of response to
etrolizumab were identified in cohort 1, and gene expression in
flow cytometrysorted T cells was evaluated in cohort 2. In
cohort 1, clinical remission was defined as total Mayo Clinic
Score25 2, with no individual subscore >1, and mucosal
healing was defined as endoscopic score 1.
Biopsy Collection
Colonic biopsies were collected from patients in cohort 1
during flexible sigmoidoscopy or full colonoscopy at screening,
week 6, and week 10.11 Biopsies were taken from the most
inflamed area of the colon within 10 to 40 cm of the anal verge
(avoiding necrotic areas) and placed into RNAlater (Life Tech-
nologies, Carlsbad, CA) or formalin.
In cohort 2, colonic biopsies were taken from inflamed and/
or uninflamed areas of the colon and placed into RNAlater,
formalin, or processed immediately for cell sorting.
RNA Isolation and Sequencing
RNAlater biopsies were homogenized using Tissuelyzer and
RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden,
Germany) according to manufacturer’s instructions. RNA
integrity was assessed using the Agilent RNA 6000 Pico Kit on
Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA) and
quantitated using the Invitrogen Quant-iT RNA Assay Kit (Life
Technologies) or NanoDrop (Thermo Scientific, Waltham, MA).
Total RNA (RNA integrity number >5; 250 ng) was put into
the Illumina TruSeq RNA Sample Preparation Kit v2 protocol
and run in conjunction with Biomek liquid handling platforms
(Beckman Coulter Life Sciences, Brea, CA). RNA libraries were
evaluated using the Agilent 2200 TapeStation HighSensitivity
D1K Tape and quantitative polymerase chain reaction (qPCR)
with the KAPA Library Quantification Kit for Illumina
sequencing. Then 2 nM of library (12 samples per lane) was
loaded for cluster generation and sequenced on the Illumina
HiSeq 2000 Sequencing System at 2  50 base pairs read length
plus index read. Reads that passed quality filters were deter-
mined, and fastq files were generated by Illumina CASAVA v1.8.
Identification of Differentially Expressed Genes
Processing and analysis of the RNA sequencing data were
performed using the R programming language (http://www.r-
project.org) along with packages from the Bioconductor
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were processed using the HTSeqGenie Bioconductor package.
Reads were aligned to the reference human genome sequence
(National Center for Biotechnology Information build 37) using
the Genomic Short-Read Nucleotide Alignment Program algo-
rithm.26 Uniquely aligned read pairs that fell within exons
were counted to estimate individual gene expression levels. For
inclusion, genes were required to have >10 reads in 4
samples.
Two approaches were taken to identify differentially
expressed genes in etrolizumab-treated patients: (1) identifi-
cation of individual genes associated with clinical remission in
response to etrolizumab and (2) gene-set enrichment using
predefined groups of immune cell genes derived from com-
parisons of sorted immune cells defined by Abbas et al27
(Supplementary Table 1).
To calculate differential expression, we used the DESeq2
Bioconductor package28 that fits a negative binomial general-
ized linear model to determine the log-fold change and P value
for differences between groups. The default library size esti-
mation method was used to account for differences in
sequencing depth. The response variable was clinical remission
at the primary endpoint of the study.11 Technical aspects of the
sequencing runs and the endoscopic subscore at the screening
visit were also incorporated in the model. Endoscopic subscore
at screening was not prognostic of clinical remission at week 10
in cohort 1.11 For our statistical analysis, nominal (nonmultiple
test-corrected) P values were used to rank candidate genes
associated with clinical remission.11
Gene set enrichment analysis was used to characterize
differences between clinical remitters and nonremitters in anti-
TNFnaïve patients treated with etrolizumab. This analysis
was implemented using the GSEAlm Bioconductor package.29
The Wald statistic generated by the DESeq2 algorithm was
aggregated by summing the test statistics for a gene set and
dividing by the square root of the gene-set size. This gene-set
statistic was compared with a set of null statistics derived by
permuting the clinical remission sample labels and recalculat-
ing the Wald statistic for differences between the permuted
groups. An empirical P value was calculated by counting the
number of permuted gene-set statistics that were more
extreme (ie, further from 0) than the gene-set statistic calcu-
lated for the true sample labels.Cell Sorting From Colonic Biopsies
From Cohort 2
Colonic biopsies from cohort 2 were processed to a single-
cell suspension. Mononuclear cells were extracted by incuba-
tion with 5 mM 1,4-dithiothreitol, followed by digestion with
1.5 mg/mL collagenase VIII and 0.05 mg/mL DNase I (Sigma, St
Louis, MO for all reagents) then stained with Live/Dead stain
(Life Technologies); CD45 PeCy5, TCRab PeCy7, CD8a allo-
phycocyanin Cy7, CD4 Pacific Blue, aE integrin fluorescein
isothiocyanate, b7 integrin allophycocyanin (all from Biolegend,
London, UK), and CD8b phycoerythrin (Beckman Coulter).
TCRabþCD4þ or TCRabþCD8þ T cells were sorted based on
their expression of aE and b7 integrin directly into RLT buffer
(Qiagen) containing b-mercaptoethanol. RNA was isolated using
PicoPure RNA isolation kit (Life Technologies). Purity of the
sorted populations was assessed to ensure samples had 85%purity. Sorted T cells from inflamed biopsies were used for
analysis in UC patients when available (11 of 13 patients).Gene Expression Analysis by Quantitative
Polymerase Chain Reaction
RNA isolated from RNAlater biopsies was reverse tran-
scribed into complementary DNA using the High-Capacity cDNA
Reverse Transcription Kit (Life Technologies). Gene expression
levels were measured by qPCR using the BioMark HD System
(Fluidigm, South San Francisco, CA) with TaqMan PreAmp
Master Mix (Life Technologies) and reagents (Fluidigm, South
San Francisco, CA) using Taqman Gene Expression assays of
respective genes (Life Technologies), according to manufac-
turer’s instructions. Target gene expression was normalized to
glyceraldehyde-3-phosphate dehydrogenase (phosphorylating)
expression using the DCt method. Biopsies with missing aE
(n ¼ 4) or GZMA (n ¼ 1) due to study logistical issues and data
quality control were not included.
The top 45 differentially expressed genes identified from
RNA sequencing analyses were annotated to leukocyte subsets
based on their mean expression level in flow cytometry sort-
purified peripheral immune cells.27 qPCR analysis of baseline
colonic GZMA or aE expression was used to categorize patients
into GZMAhigh or aEhigh (greater than or equal to median) and
GZMAlow or aElow (less than median) subgroups.Immunohistochemistry Quantification
Formalin-fixed tissue samples were obtained from both
cohort 111 and cohort 2 patients. Geboes scoring and immu-
nohistochemistry of aE were performed according to the
protocol described previously11 and adapted for immunofluo-
rescence for co-staining. For dual immunofluorescence studies
in cohort 2, anti-granzyme A polyclonal goat IgG (R&D Systems,
Minneapolis, MN) was incubated for 60 minutes at 37C. Anti-
goat Omnimap-HRP was used as detection, and 40,6-diamidino-
2-phenylindole and hematoxylin II were used to counterstain
the sections (Ventana Medical Systems, Inc, Tucson, AZ).Statistical Analysis
Statistical testing was performed using the Mann-Whitney
test, Wilcoxon matched-pairs signed rank test, or the Fisher’s
exact test, as appropriate, using Prism (GraphPad Software Inc.,
La Jolla, CA) or JMP (SAS Institute Inc, Cary, NC). No adjust-
ments for multiple comparisons were performed. Subgroup
analyses using the sample median cutoff were performed for
granzyme A and aE. Positive predictive value was defined as
biomarkerhigh patients in remission/biomarkerhigh patients and
negative predictive value as biomarkerlow patients not in
remission/biomarkerlow patients.Results
Patient Demographics and Baseline
Characteristics
The demographics and baseline characteristics of
patients who participated in cohort 111 (n ¼ 110) and
cohort 2 (n ¼ 21; unpublished data, 2014) have been
detailed.
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Baseline Biopsies of AntiTumor Necrosis
Factor-Naïve Clinical Remitters Treated
With Etrolizumab
In cohort 1 antiTNF-naïve patients, T-cellassociated
genes were significantly enriched at baseline in clinical
remitters compared with nonremitters (P < .05; Figure 1A).
Neutrophil-associated genes were significantly down-
regulated in clinical remitters (P < .01; Figure 1B). Gene-
set enrichment analysis of DC-, monocyte-, and
B-cellassociated genes showed no significant baseline
differences between clinical remitters and nonremitters
(Supplementary Figure 1).
Clustering analysis of the top differentially expressed
genes in antiTNF-naïve etrolizumab-treated patients
showed that the main cluster of clinical remitters had
up-regulation of genes with higher expression in
sort-purified T cells (ITGAE, GZMA, GPR15, FGF9, PHF14,
FAM125B, TMEM200A, TMIGD2, KLRB1, ECH1, FOXM1, and
CPA2) and down-regulation of genes with higher expression
in sort-purified neutrophils (VNN2, TMEM154, and LRRC4;
Supplementary Figure 2).
Increased Granzyme A (GZMA) in aEþ
T Cells From Ulcerative Colitis Patients
In flow cytometrysorted T cells isolated from colonic
biopsies from UC patients in cohort 2 (Supplementary
Figure 3), GZMA gene expression was significantly
up-regulated in CD4þaEþ compared with CD4þaE T cells
(P < .0001; Figure 2A); the level of granzyme A in CD4þaEþ
cells was also significantly higher in UC patients compared
with non-IBD controls (P < .05; Figure 2A). GZMA gene
expression was positively correlated with aE gene expres-
sion in sorted CD4þaEþ cells, but not CD8þaEþ cells, fromFigure 1. Differences in baseline colonic biopsy gene expre
with etrolizumab. Distribution of curated (A) T-cell and (B)
antiTNF-naïve etrolizumab-treated patients. P value was emp
set statistics that were more extreme than the gene-set statistic
remitter to nonremitter gene-set statistic.UC patients (Spearman r ¼ 0.76; 95% confidence interval
[CI]: 0.280.94; Figure 2B); other effector genes such as
perforin and Fas ligand expression were also significantly
positively correlated with GZMA and aE in sorted CD4þaEþ
cells (Supplementary Figure 4), but not CD8þaEþ cells (data
not shown), from UC patients. Consistent with data from
cohort 2, gene expression of GZMA and ITGAE was positively
correlated in baseline colonic biopsies from cohort 1 (etro-
lizumab: Spearman r ¼ 0.48; 95% CI: 0.270.65; placebo:
Spearman r ¼ 0.61; 95% CI: 0.350.78; Figure 2C). Colonic
biopsy GZMA expression was significantly correlated with
the number of aEþ cells in the crypt epithelium (epithelial-
associated aEþ cells) and LP in colonic biopsies from cohort
1 (crypt epithelium: Spearman r¼ 0.45; 95% CI: 0.210.64:
LP: Spearman r ¼ 0.30; 95% CI: 0.060.50; Figure 2D).
Dual immunofluorescence analysis showed that granzyme A
staining was limited to a subset of aEþ cells in colonic tis-
sue, with the majority of aEþ granzyme Aþ cells appearing
to localize to the crypt epithelium (Figure 2E). These data
suggest that aEþ cells may be a source of granzyme A in the
colon.Baseline Characteristics and Enrichment of
Clinical Remission and Mucosal Healing Using
ITGAE and GZMA
Both aE integrin (ITGAE) and granzyme A (GZMA) were
identified by differential gene expression analysis. Enrich-
ment of clinical remission (Figure 3A) and mucosal healing
(Figure 3B) in response to etrolizumab was observed in
cohort 1 patients with high baseline colonic biopsy GZMA
gene expression (clinical remission: all patients (positive
predictive value/negative predictive value): 100 mg,
41%/94%; 300 mg þ LD, 18%/95%; antiTNF-naïve (pos-
itive predictive value/negative predictive value): 100 mg,ssion between clinical remitters and nonremitters treated
neutrophil-associated genes in baseline colonic biopsies of
irically calculated by counting the number of permuted gene-
calculated for the true sample labels. X-axis represents clinical
Figure 2. Increased granzyme A in aEþ T cells in UC patients.
(A) TCRabþ CD4þ and CD8þ T cells from colonic biopsies
from cohort 2 were sort purified by aE expression. CD4þaEþ
T cells from UC patients had increased granzyme A (GZMA)
expression compared with sorted CD4þaE T cells from UC
patients and CD4þaEþ T cells from non-IBD controls. (B)
GZMA and aE gene expression was significantly correlated in
sorted CD4þaEþ T cells, but not sorted CD8þaEþ T cells from
UC patients in cohort 2. In cohort 1, GZMA gene expression
was significantly correlated with (C) aE gene expression
(dotted lines indicate qPCR median cutoff) and (D) the num-
ber of aEþ cells in the epithelium and LP in colonic biopsies.
(E) Representative immunofluorescence co-staining of gran-
zyme A and aE in a colonic biopsy sample from cohort 2. *P <
.05; ****P < .0001.
February 2016 Predictive Biomarkers of Etrolizumab Response 481
BA
SI
C
AN
D
TR
AN
SL
AT
IO
NA
L
AT75%/88%; 300 mg þ LD, 50%/100%). Enrichment of clin-
ical remission in aEhigh patients in cohort 1 has been
detailed.11 Enrichment of mucosal healing was observed in
aEhigh patients in cohort 1 in response to 100-mgetrolizumab (Supplementary Figure 5). The combination of
ITGAE and GZMA, while resulting in small patient subsets,
showed a further enrichment of clinical remission
(Supplementary Table 2).
Baseline clinical characteristics were balanced across
treatment groups in both the ITGAE and GZMA biomarker
subgroups, with the exception of older age and lower
immunosuppressant use in the GZMAhigh group compared
with the GZMAlow group (Supplementary Table 2). There was
no significant difference in the distribution of baseline GZMA
or aE11 by previous anti-TNF use (Supplementary Figure 6).
Although overall Mayo Clinic score was similar between aE
subgroups, endoscopy score was slightly lower in the aEhigh
group (Supplementary Table 3). No difference was observed
in the GZMAhigh and GZMAlow subgroups for total Mayo Clinic
score or subscores (Supplementary Table 3).
A subset of patients had biopsies available for histologic
analysis.11 aElow patients had higher modified Geboes
scores30 at baseline than aEhigh patients (mean ± SD, 2.3
± 0.8 and 1.7 ± 0.9, respectively; P < .01); no significant
difference was observed between GZMA subgroups
(Supplementary Table 2).Post-Treatment Effects of Etrolizumab in
Biomarkerhigh and Biomarkerlow Patients
At baseline, the number of epithelial-associated aEþ cells
was significantly higher in both aEhigh and GZMAhigh patients
than aElow and GZMAlow patients, respectively (median
± median absolute deviation, 5.6 ± 2.6 in both aEhigh and
GZMAhigh vs 2.6 ± 1.6 and 2.9 ± 1.7 in aElow and GZMAlow
patients respectively; P < .01 both; Figure 4A). All epithelial-
associated aEþ cells were included in this analysis, as no co-
stains (eg, CD3 or CD4) were used. Etrolizumab treatment
significantly reduced the number of epithelial-associated
aEþ cells at week 10 in aEhigh (median ± median absolute
deviation, 33% ± 25%; P < .05) and GZMAhigh patients
(median ± median absolute deviation,: 36% ± 22%;
P < .01), while there was no significant reduction in
epithelial-associated aEþ cells in aElow and GZMAlow pa-
tients post-etrolizumab treatment (Figure 4B). Etrolizumab
treatment also significantly changed gene expression in
GZMAhigh etrolizumab-treated patients relative to placebo.
T-cellassociated genes (aE, granzyme A, and granzyme B;
P < .05; Figure 5A) and cytokines and chemokines (inter-
leukin 17F, interleukin 8, CCL4, and CXCL1; P < .05;
Figure 5B) were reduced in expression at week 10 in
GZMAhigh etrolizumab-treated patients compared with pla-
cebo. There was no significant difference in these genes
between placebo and etrolizumab-treated patients in the
GZMAlow subgroup at week 10. GZMAhigh patients had higher
expression of aE, granzyme B, and CCL5 and lower
expression of CXCL1 at baseline than GZMAlow patients
(Supplementary Figure 7A; P < .05P < .001). Only CCL5
was significantly decreased at week 10 in aEhigh
etrolizumab-treated patients compared with placebo
(P < .05; Supplementary Figure 8); CCL5 was significantly
higher in aEhigh patients than aElow patients at baseline
(P < .05; Supplementary Figure 7B).
Figure 3. Clinical remis-
sion and mucosal healing
by baseline GZMA
expression. (A) Clinical
remission and (B) mucosal
healing by baseline GZMA
gene expression. Baseline
colonic biopsy qPCR me-
dian value was used to
categorize patients as
GZMAhigh (greater than or
equal to median) or
GZMAlow (less than me-
dian). LD, loading dose;
TNF, tumor necrosis
factor.
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10 by biomarker subgroups. The modified Geboes score was
significantly higher at baseline in aElow patients and was
significantly reduced at week 10 among etrolizumab-treated
patients compared with those treated with placebo (P < .01;
Supplementary Figure 9). The modified Geboes score was
significantly decreased at week 10 in etrolizumab-treated
GZMAhigh patients, but not GZMAlow patients, compared
with placebo (P < .05; Supplementary Figure 9). There were
no apparent changes in the placebo arm in either biomarker
subgroup.
Discussion
Drug therapies, such as etrolizumab, that selectively
block leukocyte trafficking are emerging treatment options
for UC.12 Etrolizumab has demonstrated clinical efficacy in a
phase 2 study of moderate to severely active UC, and a
subset of patients with high colonic aE expression showed
even greater benefits.11 Identification of additional predic-
tive biomarkers for response to treatment with etrolizumab
could improve the efficiency of therapy for moderate to
severely active UC through a personalized medicine
approach. We evaluated gene expression post-hoc in base-
line biopsies from antiTNF-naïve UC patients treated with
etrolizumab and found higher baseline expression of
T-cellassociated genes, including aE integrin and gran-
zyme A, in clinical remitters. aE gene expression was found
to correlate with granzyme A gene expression, was signifi-
cantly higher in CD4þaEþ cells than CD4þaE cells sorted
from UC patients, and a subset of aEþ cells were found to
co-express granzyme A in colonic tissue. Enrichment of
clinical remission and mucosal healing was observed in both
aEhigh,11 and GZMAhigh patients. Some differences in baseline
characteristics between biomarker subgroups were
observed, including lower endoscopy and histologic scores
in aEhigh patients, but the clinical relevance is unclear.
However, neither the endoscopy score nor histologic score
at baseline were predictive of remission in response to
etrolizumab at week 10 in cohort 1. Both aEhigh and
GZMAhigh patients had higher numbers of aEþ cells in
crypt epithelium at baseline and showed decreased aEþcrypt-associated cells after etrolizumab treatment compared
with placebo. In line with the previously reported reduction
in gene expression in etrolizumab remitters,11 we found a
significant decrease in colonic biopsy gene expression of
T-cellassociated genes and inflammatory cytokines and
chemokines in GZMAhigh patients treated with etrolizumab
relative to placebo. Both of these potential predictive bio-
markers will be tested prospectively in phase 3 studies.
In this study, increased expression of T-cellassociated
genes was found in baseline biopsies of antiTNF-naïve
patients who achieved clinical remission in response to
etrolizumab. In contrast, no difference in immune cell types
was observed in TNF-inadequate responder patients in
comparison to antiTNF-naïve patients using the same gene-
set analysis in baseline biopsies (data not shown). Higher
rates of efficacy were observed in this study in antiTNF-
naïve patients and the 100-mg dose group, which could be
due to differential effects of etrolizumab on particular cell
types or other reasons related to study powering or de-
mographic differences, as discussed elsewhere.11 The speci-
ficity and exclusivity of the gene lists have been discussed.27
These cell-associated gene lists were generated based on
relatively exclusive expression of genes in a particular cell
type compared with other cell types.27 Due to the small
number of NK cellspecific genes and the fact that many of
these genes were below the minimum expression threshold
used in the analysis, our findings on NK gene-set enrichment
were inconclusive (data not shown). Minor cell populations
not included in sorted gene sets,27 such as innate lymphoid
cells and NKT cells, may also express some of the genes
identified as exclusively expressed.
Higher baseline levels of 2 biomarkers found predomi-
nantly on T cells, aE integrin and granzyme A, enriched for
clinical remission after etrolizumab treatment. Granzyme A
co-localized with aE expression in colonic biopsies, sug-
gesting that aEþ cells could be a key source of granzyme A
in the colon. Granzyme A, a serine protease present in
activated and cytotoxic NK, NKT, and T cells,31 lacks direct
cytotoxic activity at low concentrations, but has been
implicated in the release of inflammatory cytokines, such as
interleukin 1b and TNFa.32 Granzyme A has been shown to
Figure 4. Effect of etrolizumab on epithelial crypt-associated aEþ cells by biomarker stratification. Epithelial crypt-associated
aEþ cells were counted before and after treatment with etrolizumab or placebo in cohort 1. (A) Baseline distribution of epithelial
crypt-associated aEþ cells in GZMAhigh or aEhigh (greater than or equal to median) or GZMAlow or aElow (less than median)
patients where baseline colonic biopsy qPCR median value was used to categorize patients. (B) Change in epithelial crypt-
associated aEþ cells in GZMAhigh or aEhigh and GZMAlow or aElow patients after treatment with etrolizumab (combined
dose groups) or placebo. *P < .05; **P < .01. Scr, screening.
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fibronectin and proteoglycan,33 to potentially facilitate cell
migration. Emergence of granzyme Aexpressing human
immunodeficiency virusspecific T cells has been associ-
ated with slower human immunodeficiency virus disease
progression.34 Although further studies will be required to
evaluate the role of aE þgranzyme Aþ cells in intestinal
mucosa, the known functions are consistent with those of an
effector cell phenotype.
Differences in baseline biopsy gene expression were
observed based on biomarker status. Heterogeneity was
observed in baseline measurements and individual patient
data were shown to highlight variability where possible.
Small numbers of samples in placebo groups should also be
noted. Baseline CCL5 was significantly higher in the aEhigh
subgroup than the aElow subgroup, indicating that the aEhigh
environment may be associated with increased T-cell infil-
tration. GZMAhigh patients had significantly increased CCL5,
but decreased CXCL1, at baseline than GZMAlow patients.CCL5 is a chemoattractant for peripheral memory T-helper
cells, while CXCL1 is a chemoattractant for neutrophils.
GZMAhigh patients may have increased recruitment of acti-
vated T cells and altered neutrophil infiltration. These
findings support the benefits of using both of these bio-
markers for the identification of UC patients likely to
respond to etrolizumab therapy. Although aE b7þ cells also
expressed a4,10 post-hoc analysis suggests that a4 is a
pharmacodynamic10 but not a predictive biomarker of
etrolizumab (data not shown). The value of aE and GZMA as
predictive biomarkers could be due to their specificity as
surrogate markers of a subset of effector T cells that are
impacted by etrolizumab.
Changes in gene expression post treatment were also
different based on biomarker status, with significant effects
observed when substratifying patients based on GZMA
expression, supporting the idea that GZMA may be a
promising biomarker for etrolizumab response. Granzyme A
marks a subpopulation of aEþ T cells in gut mucosa, and we
Figure 5. Effect of etroli-
zumab on colonic tissue
gene expression by gran-
zyme A stratification.
Colonic biopsy gene
expression was assessed
by qPCR before and after
treatment with etrolizumab
(combined dose groups) or
placebo in cohort 1. (A)
T-cellassociated genes
and (B) cytokines and
chemokines were reduced
in colonic tissue after
treatment with etrolizumab
in GZMAhigh (greater than
or equal to median) but not
GZMAlow (less than me-
dian) patients relative to
placebo. Data are pre-
sented as fold (2DDCt)
group median ± median
absolute deviation. *P <
.05 vs placebo. Scr,
screening.
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expression in colonic biopsies as well as in sorted CD4þaEþ
cells. In sorted CD4þaEþ cells, the expression of GZMA was
significantly up-regulated in UC patients relative to controls.These biomarkers were also positively correlated with
effector molecules, such as Fas ligand and perforin, sug-
gesting that these CD4þ cells might have acquired effector
phenotypes of cytolytic lymphocytes (CD4þ cytotoxic T
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to be associated with chronic immune activation, such as in
chronic viral infections3537 and in inflammatory disease,
including CD38 and rheumatoid arthritis.39 Recent work
supports that this cell population may also play a role in UC,
where higher expression of inflammatory cytokines are
observed in CD4þaEþ T cells in inflamed biopsies from UC
patients compared with non-IBD controls (unpublished
data, 2014). The enhanced benefits of etrolizumab on clin-
ical remission and mucosal healing in patients with high
GZMA and aE gene expression in baseline colonic biopsies
support the hypothesis that increased activation and
retention of T cells in the gut may play a crucial role in the
pathobiology of UC. It should be noted that the sample size
in these studies is small and further analysis will be
required to test this hypothesis. In addition, the specificity
of these observations for etrolizumab therapy in compari-
son with other therapies will need to be evaluated.
We observed a greater histologic improvement from
baseline in etrolizumab-treated aElow patients, suggesting
increased benefits in microscopic healing in these patients
than aEhigh patients. Enrichment of clinical benefit was
observed in aEhigh patients, but the lower histologic grade at
baseline in aEhigh patients might have led to less sensitivity
for histologic changes after treatment. Histologic improve-
ment did not translate to clinical benefits in aElow patients
within the 10-week trial period of cohort 1, but patients did
achieve a histologic score similar to baseline levels of aEhigh
patients by the end of the study, and a longer treatment
period may be needed to assess the clinical benefits after
histologic healing. Compared with aE subgroups, GZMA
subgroups had balanced histologic and endoscopic scores at
baseline, but enriched clinical remission was only observed
in GZMAhigh patients.
Immunohistochemistry assessment of granzyme A
expression in a subset of aEþ cells may be equally important
for patient identification. Epithelial erosion or loss of in-
testinal epithelial cells that express E-cadherin in the setting
of active UC could further reduce the anchoring of aEþ cells
in the epithelium and therefore the quantification of aE
transcripts by qPCR. Geboes erosion subscore, but not crypt
destruction or the presence of neutrophils in the epithelium
(data not shown), was higher in aElow patients than aEhigh
patients at baseline, suggesting that aElow patients may have
increased inflammation involving erosion of the epithelium
without other differences in active disease measured by
histology. However, histologic scores were not different
between GZMAhigh and GZMAlow patients. The absence of
baseline differences between GZMA subgroups suggests that
granzyme Aþ cells may be less affected by epithelial loss and
therefore be a more robust and stable biomarker without
the confounding effects of epithelial erosions that may
impact aE levels.
The potential predictive biomarker profile identified in
this study is the first of its kind in a moderate to severely
active UC patient population and could pave the way for a
personalized medicine approach to therapeutic decision
making. The pathobiology of IBD is complex, and custom-
izing therapy to a patient’s predictive biomarker profile willbe important in creating optimal therapeutic responses and
tailoring therapy for patients. Larger studies are underway
to validate the findings of this study, with prospective an-
alyses of baseline biomarker levels and exploration of clin-
ically relevant biomarker cutoffs to test for enriched
response to etrolizumab.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
j.gastro.2015.10.041.References
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Supplementary Figure 1. Differences in baseline colonic biopsy gene expression between antiTNF-naïve etrolizumab-
treated clinical remitters and nonremitters. Distribution of curated DC-, monocyte-, and B-cellassociated genes in base-
line colonic biopsies of antiTNF-naïve etrolizumab-treated patients. P value is empirically calculated by counting the number
of permuted gene-set statistics that were more extreme than the gene-set statistic calculated for the true sample labels. X-axis
represents clinical remitter to nonremitter gene-set statistic.
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Supplementary Figure 2. Top differentially expressed genes between anti-TNFnaïve etrolizumab-treated clinical remitters
and nonremitters at baseline. Dendrogram showing unsupervised clustering analysis of top differentially expressed genes
between anti-TNFnaïve etrolizumab-treated clinical remitters and nonremitters, as measured by qPCR in baseline colonic
biopsies from all etrolizumab-treated patients in cohort 1. Each gene is color coded to reflect the leukocyte subsets with the
highest expression of the gene of interest based on gene expression database of flow cytometry sort-purified cells.27 Genes
shown in gray are not listed in the database or have low expression across all leukocyte subsets.
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Supplementary Figure 3. Sort strategy and qPCR profiling of aEþ and aE T cells. (A) Biopsies from UC patients and healthy
controls enrolled in cohort 2 were sorted based on size and single cells (top row), then live CD45þ TCRabþ (middle row) were
further sorted into CD4þaEb7þ and CD4þaEb7 cell populations and CD8þaEb7þ and CD8þaEb7 cell populations (bottom
row). Healthy control is shown. (B) qPCR of sort purified cells for the sort parameters aE, b7, CD4, and CD8.
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Supplementary Figure 4. Correlation of aE and effector
molecule gene expression in flow cytometry sort-purified
CD4þaEþ cells in UC patients. Sort-purified CD4þaEþ cells
from cohort 2 were evaluated for gene expression of effector
molecules. The correlation in gene expression between
effector molecules perforin, Fas ligand with granzyme A, and
aE in sort purified CD4þaEþ cells in UC patients is shown.
Supplementary Figure 5. Proportion of patients with
mucosal healing by biomarker aE stratification. Baseline
colonic biopsy qPCR median value was used as cutoff to
categorize patients as aEhigh (greater than or equal to median)
or aElow (less than median).
Supplementary Figure 6. Distribution of baseline colonic
gene expression of granzyme A by dose group and anti-TNF
status. Granzyme A gene expression relative to GAPDH
expression in baseline colonic biopsies from cohort 1. The
dotted line indicates the median.
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Supplementary Figure 7. Distribution of baseline gene expression of aE, granzyme B, CXCL1, and CCL5 by biomarker status
and treatment group. Baseline colonic biopsy gene expression was assessed by qPCR in cohort 1. Baseline colonic biopsy
qPCR median value was used as cutoff to categorize patients as granzyme Ahigh or aEhigh (greater than or equal to median) or
granzyme Alow or aElow (less than median). (A) aE, granzyme B, CCL5, and CXCL1 gene expression relative to glyceraldehyde-
3-phosphate dehydrogenase (phosphorylating) (GAPDH) expression in baseline colonic biopsy by granzyme A status. (B)
CCL5 expression relative to GAPDH in baseline colonic biopsy by aE status. NS, not significant; *P < .05; **P < .01; ***P< .001.
Supplementary Figure 8. Effect of etrolizumab on CCL5
colonic biopsy gene expression by aE stratification. Colonic
biopsy gene expression was assessed by qPCR before and
after treatment with etrolizumab or placebo in cohort 1.
Baseline colonic biopsy qPCR median value was used as
cutoff to categorize patients as aEhigh (greater than or equal
to median) or aElow (less than median). Decreased CCL5
expression in colonic biopsy in aEhigh patients treated with
etrolizumab, but not aElow patients relative to placebo was
observed. Data presented as fold (2DDCt) group median
± median absolute deviation. P values correspond to the
comparison between etrolizumab and placebo. *P < .05
(vs placebo). SCR, screening.
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Supplementary Figure 9. Baseline and post-treatment histologic score by biomarker stratification. Histologic activity was
evaluated using the modified Geboes score30 for biopsies taken at the screening visit and week 10 in cohort 1. Baseline
colonic biopsy qPCR median value was used as cutoff to categorize patients as granzyme Ahigh or aEhigh (greater than or equal
to median) or granzyme Alow or aElow (less than median). Change in modified Geboes score before and after treatment with
etrolizumab or placebo by baseline biopsy (A) aE or (B) granzyme A gene expression levels. *P < .05; **P < .01.
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Supplementary Table 1.Curated Gene Lists of Sorted
Cell Subsets
T cells
Symbol Gene name
CD3E CD3e molecule, epsilon (CD3-TCR complex)
CTLA4 Cytotoxic T-lymphocyte-associated protein 4
CD8B CD8b molecule
CD3D CD3d molecule, delta (CD3-TCR complex)
CD3G CD3g molecule, gamma (CD3-TCR complex)
ICOS Inducible T-cell co-stimulator
DGKA Diacylglycerol kinase, alpha 80 kDa
TRAT1 T cell receptor associated transmembrane adaptor 1
GPR15 G protein-coupled receptor 15
INPP4B Inositol polyphosphate-4-phosphatase, type II, 105 kDa
ZBED2 zinc finger, BED-type containing 2
CAMK4 Calcium/calmodulin-dependent protein kinase IV
PIK3IP1 Phosphoinositide-3-kinase interacting protein 1
CD6 CD6 molecule
CD5 CD5 molecule
GZMK Granzyme K (granzyme 3; tryptase II)
CXCR6 Chemokine (C-X-C motif) receptor 6
CDK1 Cyclin-dependent kinase 1
TCF7 Transcription factor 7 (T-cell specific, HMG-box)
Neutrophils
Symbol Gene name
MANSC1 MANSC domain containing 1
TNFRSF10C Tumor necrosis factor receptor superfamily,
member 10c, decoy without an intracellular
domain
CXCR1 Chemokine (C-X-C motif) receptor 1
CXCR2 Chemokine (C-X-C motif) receptor 2
FFAR2 Free fatty acid receptor 2
PROK2 Prokineticin 2
CMTM2 CKLFlike MARVEL transmembrane domain
containing 2
KRT23 Keratin 23 (histone deacetylase inducible)
FCGR3B Fc fragment of IgG, low affinity IIIb, receptor
(CD16b)
CCR3 Chemokine (C-C motif) receptor 3
CLC Charcot-Leyden crystal protein
R3HDM4 R3H domain containing 4
Dendritic cells
Symbol Gene name
ADAM12 ADAM metallopeptidase domain 12
CCL17 Chemokine (C-C motif) ligand 17
CD1A CD1a molecule
CD1B CD1b molecule
CD1E CD1e molecule
NR4A3 Nuclear receptor subfamily 4, group A, member 3
CXCL11 Chemokine (C-X-C motif) ligand 11
GPR157 G protein-coupled receptor 157
FSCN1 Fascin homolog 1, actin-bundling protein
SLCO5A1 Solute carrier organic anion transporter family,
member 5A1
RAB30 RAB30, member RAS oncogene family
PDCD1LG2 Programmed cell death 1 ligand 2
USP18 Ubiquitin specific peptidase 18
Supplementary Table 1.Continued
Dendritic cells
Symbol Gene name
NUB1 Negative regulator of ubiquitin-like proteins 1
C5orf20 Chromosome 5 open reading frame 20
CLEC10A C-type lectin domain family 10, member A
ARHGAP22 Rho GTPase activating protein 22
Monocytes
Symbol Gene name
CTSD Cathepsin D
IL3RA Interleukin 3 receptor
VCAN Versican
PTX3 Pentraxin 3
SERPINB2 Serpin peptidase inhibitor
MMP19 Matrix metallopeptidase 19
CLEC5A C-type lectin domain family 5
BHLHE41 Basic helix-loop-helix family
PLD3 Phospholipase D family
SLC31A1 Solute carrier family 31 (copper transporters)
ZEB2 Zinc finger E-box binding homeobox 2
TNFSF15 Tumor necrosis factor (ligand) superfamily
DFNA5 Deafness
KLF10 Kruppel-like factor 10
PID1 Phosphotyrosine interaction domain containing 1
B cells
Symbol Gene name
VPREB3 Pre-B lymphocyte 3
FCRL5 Fc receptor-like 5
MZB1 Marginal zone B and B1 cell-specific protein
PNOC Prepronociceptin
CD19 CD19 molecule
CD79A CD79a molecule, immunoglobulin-associated alpha
MS4A1 Membrane-spanning 4-domains, subfamily A,
member 1
DTNB Dystrobrevin, beta
TCL1A T-cell leukemia/lymphoma 1A
TNFRSF17 Tumor necrosis factor receptor superfamily,
member 17
FCRL2 Fc receptor-like 2
BLK B lymphoid tyrosine kinase
FCRL1 Fc receptor-like 1
GNG7 Guanine nucleotide binding protein (G protein),
gamma 7
SPIB Spi-B transcription factor (Spi-1/PU.1 related)
RALGPS2 Ral GEF with PH domain and SH3 binding motif 2
FAM129C Family with sequence similarity 129, member C
OSBPL10 Oxysterol binding protein-like 10
BANK1 B-cell scaffold protein with ankyrin repeats 1
KLHL14 Kelch-like 14 (Drosophila)
CPNE5 copine V
CD79B CD79b molecule, immunoglobulin-associated beta
POU2AF1 POU class 2 associating factor 1
BLNK B-cell linker
TNFRSF13C Tumor necrosis factor receptor superfamily,
member 13C
NOTE. Genes used for each of the leukocyte subsets in the
gene-set enrichment analysis are listed.
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Supplementary Table 3.Baseline Characteristics by Biomarker Subgroups
GZMAlow
(n ¼ 54)
GZMAhigh
(n ¼ 55)
aElow
(n ¼ 53)
aEhigh
(n ¼ 53)
Age, y, mean ± SD 37 ± 14 43 ± 13a 39 ± 14 41 ± 13
Male, n (%) 34 (63) 30 (55) 32 (60) 30 (57)
Duration of UC, y, mean (range) 9.1 (0.330.1) 9.3 (0.540.9) 5.6 (0.330) 8 (141)
Concomitant medication use, n (%)
Corticosteroids 22 (41) 25 (46) 24 (45) 23 (43)
Immunosuppressants 30 (56) 14 (25)b 24 (45) 19 (36)
Previous anti-TNF use 34 (63) 33 (60) 32 (60) 34 (64)
Previous anti-TNF failure 33 (61) 30 (55) 30 (57) 32 (60)
Disease extent, n (%)
Left-sided colitis 23 (43) 17 (31) 22 (42) 17 (32)
Pancolitis/extensive disease 16 (30) 26 (48) 18 (34) 22 (42)
Rectosigmoid 14 (26) 12 (22) 12 (23) 14 (26)
Other 1 (2) 0 1 (2) 0
Disease activity, mean ± SD
Mayo Clinic score 9.2 ± 1.5 9.5 ± 1.5 9.7 ± 1.5 9.1 ± 1.4
Rectal bleeding 1.8 ± 0.6 1.9 ± 0.7 1.8 ± 0.7 1.7 ± 0.6
Stool frequency 2.5 ± 0.7 2.6 ± 0.6 2.7 ± 0.7 2.5 ± 0.7
Endoscopy 2.6 ± 0.5 2.6 ± 0.5 2.8 ± 0.4 2.5 ± 0.5c
Physician global assessment 2.3 ± 0.6 2.4 ± 0.5 2.4 ± 0.6 2.3 ± 0.5
Modified Geboes score, mean ± SD (n) 2.1 ± 0.8 (47) 1.9 ± 0.9 (48) 2.3 ± 0.8 (46) 1.7 ± 0.9c (46)
NOTE. Gene expression of baseline colonic biopsies using qPCR median as cutoff was used to categorize patients as
biomarker high and low.
aP < .05 vs GZMAlow.
bP < .01 vs GZMAlow.
cP < .01 vs aElow.
Supplementary Table 2.Clinical Remission by Biomarker
Subgroups
AntiTNF-naïvea
100-mg dose group aEhigh aElow
GZMAhigh 86 (6/7) 0 (0/1)
GZMAlow 0 (0/2) 20 (1/5)
300 mg þ LD dose group aEhigh aElow
GZMAhigh 50 (1/2) 50 (2/4)
GZMAlow No data 0 (0/6)
All patientsb
100-mg dose group aEhigh aElow
GZMAhigh 55 (6/11) 17 (1/6)
GZMAlow 0 (0/5) 13 (1/8)
300 mg þ LD dose group aEhigh aElow
GZMAhigh 9 (1/11) 33 (2/6)
GZMAlow 0 (0/6) 8 (1/13)
NOTE. Gene expression of baseline colonic biopsies using
qPCR median as cutoff was used to categorize patients as
biomarker high and low.
aValues shown are percentage of antiTNF-naïve
etrolizumab-treated patients in remission at week 10 (n in
remission/total).
bValues shown are percentage of etrolizumab-treated
patients in remission at week 10 (n in remission/total).
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